TY - JOUR
T1 - Engineering tumor cell targeting in nanoscale amyloidal materials
AU - Unzueta, Ugutz
AU - Seras-Franzoso, Joaquin
AU - Céspedes, María Virtudes
AU - Saccardo, Paolo
AU - Cortés, Francisco
AU - Rueda, Fabián
AU - Garcia-Fruitós, Elena
AU - Ferrer-Miralles, Neus
AU - Mangues, Ramon
AU - Vázquez, Esther
AU - Villaverde, Antonio
PY - 2017/1/6
Y1 - 2017/1/6
N2 - © 2016 IOP Publishing Ltd. Bacterial inclusion bodies are non-toxic, mechanically stable and functional protein amyloids within the nanoscale size range that are able to naturally penetrate into mammalian cells, where they deliver the embedded protein in a functional form. The potential use of inclusion bodies in protein delivery or protein replacement therapies is strongly impaired by the absence of specificity in cell binding and penetration, thus preventing targeting. To address this issue, we have here explored whether the genetic fusion of two tumor-homing peptides, the CXCR4 ligands R9 and T22, to an inclusion body-forming green fluorescent protein (GFP), would keep the interaction potential and the functionality of the fused peptides and then confer CXCR4 specificity in cell binding and further uptake of the materials. The fusion proteins have been well produced in Escherichia coli in their full-length form, keeping the potential for fluorescence emission of the partner GFP. By using specific inhibitors of CXCR4 binding, we have demonstrated that the engineered protein particles are able to penetrate CXCR4+ cells, in a receptor-mediated way, without toxicity or visible cytopathic effects, proving the availability of the peptide ligands on the surface of inclusion bodies. Since no further modification is required upon their purification, the biological production of genetically targeted inclusion bodies opens a plethora of cost-effective possibilities in the tissue-specific intracellular transfer of functional proteins through the use of structurally and functionally tailored soft materials.
AB - © 2016 IOP Publishing Ltd. Bacterial inclusion bodies are non-toxic, mechanically stable and functional protein amyloids within the nanoscale size range that are able to naturally penetrate into mammalian cells, where they deliver the embedded protein in a functional form. The potential use of inclusion bodies in protein delivery or protein replacement therapies is strongly impaired by the absence of specificity in cell binding and penetration, thus preventing targeting. To address this issue, we have here explored whether the genetic fusion of two tumor-homing peptides, the CXCR4 ligands R9 and T22, to an inclusion body-forming green fluorescent protein (GFP), would keep the interaction potential and the functionality of the fused peptides and then confer CXCR4 specificity in cell binding and further uptake of the materials. The fusion proteins have been well produced in Escherichia coli in their full-length form, keeping the potential for fluorescence emission of the partner GFP. By using specific inhibitors of CXCR4 binding, we have demonstrated that the engineered protein particles are able to penetrate CXCR4+ cells, in a receptor-mediated way, without toxicity or visible cytopathic effects, proving the availability of the peptide ligands on the surface of inclusion bodies. Since no further modification is required upon their purification, the biological production of genetically targeted inclusion bodies opens a plethora of cost-effective possibilities in the tissue-specific intracellular transfer of functional proteins through the use of structurally and functionally tailored soft materials.
KW - cell-targeted delivery
KW - CXCR4
KW - functional amyloids
KW - nanoparticles
KW - recombinant proteins
KW - tumor-homing peptides
U2 - 10.1088/0957-4484/28/1/015102
DO - 10.1088/0957-4484/28/1/015102
M3 - Article
SN - 0957-4484
VL - 28
JO - Nanotechnology
JF - Nanotechnology
IS - 1
M1 - 015102
ER -